PB-YSR-21 by Bagian Kepegawaian & HKTL, chalidbest

DIBACAKAi'I PADA ; * SIIIPOSIUNI PRfTEll LABOR.'.
PIT POGI20. 18 SEPTEITBER 2OIJ
}IARI'LAN ROO]T| , Jll.}IARIOT HOTEL, ]TIED.{\
TOCOL}'TIC] AND NEI.TROPROTECTION IN PRETERT{ LABOR
Yusran'ati
HKFM PADANG
Preterm birth (PTB) is any deliverl', regardless of birtlr weight, that occurs betbre 3?
cornpleted weeks from the first da.v of the last menstrual period. Pretenn delivery is the leading
cause of the perinatal morbiditl' and motality' u,orldwide. Almost l3 rnillion babies every 
-vear
r.vorldrvide are bom preterm. An estimated 28 96 of the 4 rnillion annual neonatal deaths
rvorldlvide are directly' attributable to preterm birth . Over a million babies ever)' year die of
prematurit)'. So. every minutc 2 babies die of pretenn birth . Accounts for 75% of perinatal
rnortalit_v" and rnake up more than 50orb of long-tenn morbiditv associated rvith poor perinatal
outcomes . Oler 8-5 o/o occut in Asia and Africa. The highest rates in Africa and North Arnerica
(11.9% and 10.694).
'[he incidence of disability and neurodevelopmental problems among survirals remains high
and problerntie . Major disabilities (moderate-severe mental retardation. sensorineuml hearing
losstblindness cerebralpalsl,', and epilepsy) present in up to 25% of VLBW.
Neurodevelopmental dysfunctions (leaming disabilities. low arerage IQ scores, AI)HD,
neuropsycltological delicits, visual motor integratiorr. tempera,nent difficulties, language delays,
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emotional problems and regulatorl' disorders) present in 50 -70o;ir of VLBW. Tlose deficits can
be seen in premature intbnt rvith iYHPVL or rvithout anv ultrasound abnormality.
Cost of Preterm Birth: lvledicalcare sen,ices: 16.9 billion ( S 33,200 per preterm infant) - 2i3
total cost. Maternal delivery cost: 1.9 billion ( $ 3,900 per prererrr infant). Spccial educarion
sen'ices: l.l billion ( $ 2,200 per pretenx infant)" Lost household and labor rnarket prqducti'i-ry-:
5.7 billion ( Sl 1,200 per pretenn infant) . The annual cost of PTB irr US esceeds $ 5 biilion and
the rate of PTB has increased in recent years . Treatmenr should be initiated onl1, once the diagrrosis
is rnade The diagnosis of spontaneous pretenn labor (PTL) and accurate preeliction of p1'B is
notoriously difficutt. PTL is a clinical diagnosis. Regular contraetions rvrth cervieal effacement
or dilatation are required for diagnosing establistred labor. The ciinical diagnosrs of pTL :
Cont-actions that are painftil. palpable, last longer than 30 seconds and occur at least 4 times per
20 minutes .Evidence of a change in the position. consisteucy, lenght an<llor dilatation of the
cervix. Contractions occtr at a frequencv of 4 times per 20 minutes or I per 60 rninutes
Accornpanied by one of the follorving : PROM, Cenical dilatation :' f cm. Effacernent :,, 50g6,
Change in cen'icai dilatation or effacement detected by serial examinations. Tlie clinical
diagnosis of PTL; Conkactions > 6 Itotu'. Clenjcal dilatation i 3 icm antl or elfhcerrrent > 80?6.
Vaginal bleeding. Documented change in the cenical eram Standard techniques of clinical
diagnosis ma,v not accurately'detect PTL, either missing the diagnosis or prornpting unnecessary
Itospitalization and treatment. Patients rnay not percei'ue confractions and that contractions are at
times difficult to differentiate fiorn benigm Braxton-Hicks contractions ol nonnal pregxanc),.
Digital assessment of the cen'ix lacks rcproducibility rvheg the dilatatign is .< 3 crn or efthceme,t
is < 80o,t,. Clinical evaluarion alone can easl,v suggest prematudty u,hen it is absent ancl miss it
when it is presen.
Clinjcal and tsiochemical Markers : A number of snrdies lral,e atternped to idelti$; clilical
and biochemical markers. Source of biologic fluid : Serum or plasma. funniotic fluid" Urine,
Vagina and cenical secretions. Saliva, Periodontal fluid.
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Cen'ical Length (TVU CL) ; Examination of the cenix rvith ultrasound is superior to vagrnal
examination. The shorter the cerv'ix, the higher the risk for PTB and vice versa. Ultrasound
assessment of the cervix in normal pregnatc.v sho*'s that cen'ical efTacement starts around 32
rveeks. In pregnancies affected b1' PTL the process may begin betneen 16 and 24 neeks.
Etlacernent begins at the intenlal os and can be visualized as uervical shortening and ftmneling, a
process that occurs before dilatation of the external os. Lesser cervical lenEh means greafer risk.
Likelihood of PTB is inversely proportional to cen'ical length measured at 18-28 vreeks. A
lenght of S 2.5 cm is the treshold for abnormal condition,
Fetal Fibronectin [FFN), An extracellirlar glycoprotein described as the glue that anaches the
fetal rnembrane to the underl-ving uterirre decidua. ls norrnalll,' absent in cervicovagfuial
secretions between r,veeks ?2 and 37 of pregnancy. Its presence (> 50 ngtrnl) beween 22 to 24
rveeks is a predictor of spontaneous PTB. Its absence makes PTB unlikel.v. Diagrrosis Diagrosrs
(lvlodern); Persistent uterine cortraetions( ) 6 flrour) and TYI] CL < 20 mm orlVU CL 20-30
rnm and FI;N 1+i .
Effotts to pre!'ent PTB can be disappointing. Obsterrics carc must focus on strategies to
impror.e the outcome of preterm inlhnts. 3070 spontaneously resolves. < I$,o:ir gir,e birth witfiin ?
days, 509ro hospitalized women give birth at term.
Preventive pro$rams or rnten-entions goals: (1) Decrease of uterine contractions to delal'
pretefin deliverl' , (2) Optimize the fetus t'or life extra-uterine .(3) Tratrsfer the mother to a
tertiary referral hospital where a neonatal intensive care unit is ar,ailable. Primary effbrr. betbre or
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dunng pregnanc!'to prevent & reduce risk . Secondary effort, eliminating or reducing risk in women
with kno$,n risk factors . Tertiary effort. initiated after the process parturition bcgun with a goal
preventing delir.ery or improving out comes for preterm infants Matemal risk factors fbr
preterm birth ,
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Tocolytic; Single or ll'Iultiple ?
Corticosteroid: Single - Multiple .Tocolytics : Acute and Mainterlance, First Choice ald
Second Choice. Tocolytics ; Abolish contractions temporarily,I)oesn't remove underlfing
stimulus, Delay delivery by hours to days. Indication; trVomen rvith pretenn labor at a gestatiorral
age at which a delay in delivery will provide benefit to the neu,bom. Because tocol-ytic therapy
generally is effective for up to 48 hours, only'rvomen *'ith feruses that r.vould benefit frorn a 48-
hour dela,v in deliverv should receive tocoll'tic treatment.
Treatment goals; delal' delivery by at least 48 hours so that corticosteroids given to the
urother can achiele their marimum fetaVneonatal effect. (Predelivery adminisffation of
betamethasone reduces the risk of neonatal death, RDS, lVH, and NEC in prernature neonates).
kor"ide time for safe transport-of the mother, if indicated, to a faciliqv that has an appropriate
lerel of neonatal care. Prolong pregnancy when there are. underlying. self-limited conditions that
can cause labor, suelr as pyelonephritis or abdominal surgery (appendectomy).
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Gestational age litrits: Lower lirnit. tocol-ltics are generally not indicated prior to ileonatal
viability' since these drugs do not delay delivery for more than a few days. Except to inhibit
contractions after a self-limited event that has been assoc'iated with preterrl labor, suclt as Ac.ute
S,'elonephritis or appendicitis u,ith appendectomy. Upper limit , Thirty-four weeks of gestation.
Contraindications ; Women rvith preterm contractions without cervical change. Cen'iral dilation
:" 3 cm, The nraternalfetal rishs of prolonging pregnancv or the risks associated lvith these dntg;s
are greater than the risks associated with pretenn birth. Established contraindications to labor
inhibition include : Intrauterine fetal demise, Lethal I'etal anomaly. Nonreassuring fetal status,
Severe preeclampsia or eclampsia, Maternal hemorrhage rvith hemodynarnic irrstabitig'.
Inuaamniotic infection, Maternal contraindications to the tocoll'tic dntg-
The selection of an appropriate labor-inhihiting agent should be based upon efficacy and
safetl'- The dmg should be safe for the mother, fetrs, and neonate. If the first tocol-vtic does not
successfull_v inhibit contractions, discontinue it and begin therapy with a seeond agent.
Concurrent use of more than one tocolytic ageot should be undertaken r.vith caution because of
the furcreased risk of side etl'ects. There are no data on the role of repeated courses of tocol,vtics
for treatnent of recurrent pretenn labor. ln patients receiving antenatal corticosteroids.
discontinue tocolytics 4S hours after administration of the first corticosteroid dose.
Options: Cy'clooxygenase inhibitors and calcium channel blockers had the highest probabilit-r-
of delaying delivery and improving rreonatal and maternal outcomes. For r.r'omen 24 to 32 rveeks
of gestation rvho are candidates tbr tocolysis. use indomethacin as first-line therapy for labor
inhibition. For w'omen 32 to 3;l weeks of gestation, use nil'edipine lbr irritial reatment of preterrn
labor. due to adverse fetal elTects of indornethacin use at this gestational age .
Indomethacin Side Effect; Maternal: Nausea, gastritis, and ernesis (4016), Platelet
dyslilnction may occtu. Alterations in matemal cardiovascular ph1'siolog,v are minimal (eg,
rnyocardial infarction. stroke). Fetal : Consffiction of the ductus arteriosus . Oligoh-r"drarnnios.
Ca channel Blocker: Meta-analysis ofl 13 randomized trials 11000 patients) specifically
comparing nifedipine versus beta-adrenergic receptor agonists: Nifedipine had feu,er delireries
uithin ? days (RR 0.82, 95% CI 0.?0-0.9?; 37 versrs 45 percent) and before 34 weeks of
gestation fRR 0.77. 959zir Cll 0.66-0.91; 48 versus 62 percent). but tlrere was no sigrrificaut
difference in deliverv within 48 hours of treafinent (RR 0.84,95q''6 CI 0.68-1.05; 21 rersus ?4
percent) Nifedipine rvas also associated Significant reductions in RDS, NEC, [VH, neonatal
jaundice- adrnission to the neonatal intensive care unit, and Had a better side effect profile.
Dose; lnitial loading dose of 20 rng orally, follorved by 20 mg orall-v in 90 minutes. lf
contractions persist, 20 rng carr be gir.en orallv every 3 to 8 hours fbr up to 7? hours, rt'"ith a
maxirnum dose of 180 mglday. ACOC suggests a 30 rng loading dose and then l0 to ?0 mg
even f-our to six hours . Lllainrerrance : There are several theoretical rationales for considering
maintenance tocolysis atter successful arrest of the initial episode of PTL: l. the underlying
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stimulus for labor may persist and cause a reculrence. 2. the nlyometritlm, havitrg expelienced a
Tecent episode of PTL, may be in a chemical state of preparedness and thus hare a low
threshold lor recurrence Matntenance tocolytic therapy is ineffective : 
'li a secorrd episode of
acute pretenn labor oceurs, the indicati<xrs fol retlEatment are the satne as for a pnmary episode.
Beta-agonists , A Cochrane revierv. rvhiclt included ll randomized trials comparing oral
beta-mimetics rvith altemative therapies or placebo for maintenance therapy after thleatened
PTL, conctuded there rvas no significant bene{it to oral beta-mimetic therap). Outcomes
evahEred included rate of NICU admission, preterm birth, perinatal mortalit-v. and perinatal
nrorbiditl'. FDA concluded that the risk of serious ad\erse events frou prolonged
terbutaline therapy of pretenn labor {be1'ond 48 to 72 llours) ounveighs any potential benefit.
The safety of this therapy rlas unclear. Risks . An FDA-cooducted search of its Adrerse Event
Reponing S1-stem (AERS) identified reporrs ol 16 maternal deaths associated with terbutaline
bet\r,een 1976 al)d 2009. Bet$een 1998 and .lul.v 2009. 12 cases of seriotls maternal
cardiovasculal.
MgSO4: A more recent report evaluating 19 RCT reveals that MgSO4 fails to reduce
delirery rate within 48 horrs.
Recprnmendatiors : L Administrate tocolytics to selected \l-omen with preterrn labor- 2.The
goal of treatment is to detay delivery so that gluoocorticoids car be administered and achieve
their maxirnal eft'ect: allolv sal'e tralrsport of the mother. or to prolong pregntulc]- lvhen there are
underlying, selfJimited causes of [abor. S.Treatrnent can be discontinued alter these goals have
been achieved. 4. The selection of an agent should be based upon efficac! and safet-r. 5 Ifthe
firs1ocol),tic agent ohosen does Dot successfrtlly inhibit preterm labor. discontinuurg it and begin
therapy w-ith a second agent. 6. Avoid routilel-v administering multiple locolytics ln patients
*ho fail therapy u'ith a single agent. 7. Not using maintenance tocol-""sis .
Fetal Neuroprotection .
Prerenr birth and lorv birth *right are important public health problents, have a higher risk
ofa dereloping neurological problems such as cerebral palsy (CP) and irnpairment ofcognitive
f'rrnction. The risks furcreases , rvith decreasing GA at bi-rth. Preterm infants bom witlt PE had a
lorver incidence of adverse CNS outcomes than without PE. The use of MgSO4 for PE ma-v.'
underlie the potential association beFveen administration of MgSO4 and CP. \'IgSO4 given
before anticipateil ea 
-y preterln brrth reduces the risk of CP in strn iving rnf'a.nts. The exact mechanisrn
ts still unkno*n, l'rvo theories tlrat describe how magnesium rnal inhibit neuronal damage :
Hypoxic-ischaem'ic darnage and Inflamatorl' damage .
Hypoxic-ischaemic dannge : cP is though to be a resuh of pelivcntricular while mater
damage that predouinates. <32 rveeks gestation. H1'poxic-ischaemic danrage is a result of low
oxygen and glucose supply; leads to excessive glutamate lelcase , Glutamate slimulates the N-
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rnerhl,-l-D-aspartate (NMDA) : MgSO4 is an NfuIDA receptor antagonist and have proven t0 be
strong neuroprotcctants in various animal models'
Inflarnafory damage : There is a strong correlation behveen spontaneous pretenri birth and
inrra.terine in{lamation. Fetal brains subjected to inflarnation that u'ere treated u'ith MgSo4 did
not display 6euronal injur-v-. associated rvith ferver dendritic processes. M-eSO4 therapy given to
wemen at risk of preterur birth substantialll' reduced the risk of CIP in their infants (RR 0'68,
95-0,6 CI 0.54-0.87).
tndication; Snminentpretenn birth ( from viabilih- to 5 3l - 6 weeks) is : Active labour
rvirh > 4 om of cerv.ical dilatation +i- PPRON{ , Planned pretenn birth fbr f'etal or maternal
indications , Singleton and nrultiple pregnancies,Nulliparous and parous , Anticipated vaginal or
Caesarean delir.eq. . Aly reason for anticipated preterrn birth . Exclusion criteria ; MgSO4
already administered lbr preeclarnpsia- eclaurpsia . < l2 lrours since discontinuation of previous
MgSO4 infusion , MgS04 contraindicated . Dosage ; t.oading dose 6 g IV over 20-30 minutes. A
maintenance infgsion of 2 g I lu for l2 ltours or until delivery, whichever comes first.
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ivlg.S(.11 ma.r bs adminisrc'rccl h<'lbrc rrrolSic dnrl* hrrc lrm clctrtd l'rom ths mtt*mal
cir'tulaiirm-'llnitldipine hts tren rrsed liri trnollsis or hltrtrtension' there is N(l)
a'smnrirtdi('.ltrm ur rh* tr* ol ltgrS()r lor thal ncurttlft'lra.lion'
Dc,ilB ) sh{tllld N{ ) l lL' rlc'lt1'cd in Qrder lo adntinistgr '[riclrslal t'lgS(], irr fctali.riop.orotiu" if tlrr* sn'miunul alxl;or li;lill itrdilrlioo$ lfur utgcnt rlsli'cr' '
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